Biora Therapeutics, Inc.

OTCPK:BIOR Stock Report

Market Cap: US$2.1m

Biora Therapeutics Management

Management criteria checks 3/4

Biora Therapeutics' CEO is Adi Mohanty, appointed in Nov 2021, has a tenure of 3.08 years. total yearly compensation is $3.14M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $10.81K. The average tenure of the management team and the board of directors is 2.7 years and 3.5 years respectively.

Key information

Adi Mohanty

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage18.3%
CEO tenure3.1yrs
CEO ownership0.5%
Management average tenure2.7yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Sep 13

Biora Therapeutics: Checking In On The Transformation

Aug 17

Biora rallies 30%, highest since November on data for drug delivery device

Aug 10

CEO Compensation Analysis

How has Adi Mohanty's remuneration changed compared to Biora Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$3mUS$574k

-US$124m

Sep 30 2023n/an/a

-US$122m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$4mUS$550k

-US$49m

Sep 30 2022n/an/a

-US$118m

Jun 30 2022n/an/a

-US$140m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$10mUS$63k

-US$179m

Compensation vs Market: Adi's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.

CEO

Adi Mohanty (57 yo)

3.1yrs

Tenure

US$3,139,017

Compensation

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Leadership Team

NamePositionTenureCompensationOwnership
Aditya Mohanty
CEO & Director3.1yrsUS$3.14m0.52%
$ 10.8k
Eric d'Esparbes
Chief Financial Officer5.6yrsUS$1.60m0.19%
$ 4.0k
Clarke Neumann
Senior VP10.3yrsUS$1.53m0.18%
$ 3.7k
Robyn Hatton
Head of Human Resourcesno datano datano data
Kevin Howe
Senior VP of Strategic Operationsno datano datano data
Sharat Singh
Head of Research2.7yrsno datano data
Paul Shabram
Head of Technical Operations2.7yrsno datano data
Ariella Kelman
Chief Medical Officer1.6yrsno datano data
James Knight
Head of Business Developmentless than a yearno datano data

2.7yrs

Average Tenure

58.5yo

Average Age

Experienced Management: BIOR's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aditya Mohanty
CEO & Director3.1yrsUS$3.14m0.52%
$ 10.8k
Brian Kotzin
Independent Director5.5yrsUS$185.11k0.041%
$ 856.2
William Chey
Member of Clinical Advisory Board SIBO & Functional Bowel Disordersno datano datano data
Anthony Lembo
Member of Clinical Advisory Board SIBO & Functional Bowel Disordersno datano datano data
Geert D'Haens
Member of Inflammatory Bowel Disease Clinical Advisory Board3.5yrsno datano data
Bruce Sands
Chairman of Inflammatory Bowel Disease Clinical Advisory Board3.5yrsno datano data
Jeffrey Alter
Independent Chairman5.9yrsUS$208.11k0.043%
$ 893.5
Mark Pimentel
Member of Clinical Advisory Board - SIBO & Functional Bowel Disordersno datano datano data
Lynne Powell
Independent Director5.8yrsUS$163.11k0.041%
$ 855.8
Severine Vermeire
Member of Inflammatory Bowel Disease Clinical Advisory Board3.5yrsno datano data
Jill Howe
Independent Director3.1yrsUS$180.11k0.040%
$ 839.8
Satish Rao
Chair of Clinical Advisory Board-SIBO/Functional Bowel Disordersno datano datano data

3.5yrs

Average Tenure

57yo

Average Age

Experienced Board: BIOR's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:41
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biora Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Julian HarrisonBTIG
Joseph PantginisH.C. Wainwright & Co.